Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study

Background.Vedolizumab is recommended as a first-line biological treatment, along with other biological drugs, in ulcerative colitis (UC) patients in whom conventional therapy failed and as a second-line biological treatment following a failure of a tumor necrosis factor alpha (TNF-α) antagonist.Objectives.We aimed to assess the real-world effectiveness and safety of vedolizumab induction therapy in UC patients treated in the scope of the National Drug Program (NDP) in Poland. Materials and methods.The endpoints were the proportions of patients who reached clinical response, clinical remission and mucosal healing at week 14.Partial Mayo scores, Mayo subscores and C-reactive protein (CRP) levels were also evaluated. Results.Our study population consisted of 100 patients (55 biologic-naïve and 45 biologic-exposed).The median total Mayo score at baseline was 10 (interquartile range (IQR): 9-11), and 52 patients (52%) had extensive colitis.The clinical response at week 14 was achieved in 83 (83%) and clinical remission in 24 (24%) cases.Mucosal healing was observed in 56 (62%) patients at week 14.In patients with prior failure of biologic treatment (n = 25), 17 (68%) responded to vedolizumab treatment.A decrease in the median CRP level (from 3.7 mg/L to 2.6 mg/L) and the median total Mayo score (from 10 to 4) was observed.No new safety concerns were recorded and no patients discontinued the treatment due to adverse events (AEs). Conclusions.Vedolizumab was effective and safe as induction therapy for UC in a Polish real-world population including patients with severely active UC and a low number of patients with prior biological treatment failures.